[12] Patent
[11] Patent No.:GC0007512  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/125431
Date of the Decision to Grant the Patent:04/Apr/2018

[21] Application No.:GCC/P/2008/11185

[22] Filing Date:28/6/2008

[30] Priority:

[33] State [32] Priority date [31] Priority No.
CU
29/6/2007
154

[72] Inventors:1- Rodriguez Martinez Gryssell Maria ،2- Vina Rodriguez, Lisel ،3- Calvo Gonzalez, Loany ،4- Cuevas Fiallo, Ariadna ،5- Chico Veliz, Ernesto ،6- Lage Davila, Agustin Bienvenido ،7- Crombet Ramos, Tania ،8- Albisa Novo , Airama ،9- Gonzalez Marinello, Gisela Maria

[73] Owner: CENTRO DE INMUNOLOGIA MOLECULAR , Calle 216 Esq. A 15, Atabey, Playa, Ciudad de la Habana AP 16040, Habana 12100, Cuba

[74] Agent: Suleiman I. Al-Ammar Law Office

  

 

  

[51]IPC:
Int. Cl.: A61K 39/385 (2006.01)

[56] Cited Documents:

-GONZALEZ, G et al., Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. HUM VACCIN., January - February 2007
-GONZALEZ, G. et al., A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. ANN. ONCOL., 1998
-WO 0245747 A1 (CENTRO INMUNOLOGIA MOLECULAR CUBA, Y OTROS) 13 June 2002
 
Examiner: Hanien H Al Ghannami

[54] HOMOGENEOUS VACCINE COMPOSITION FOR THE TUMOR TREATMENT AND ITS OBTANING METHOD
[57] Abstract: The present invention relates to the biotechnological field and particularly to the human health. More particularly, the present invention relates to a vaccine composition for therapeutic use in cancer patients. The vaccine composition of the present invention has as active principle a chemical conjugated between the human recombinant Epidermal Growth Factor (hrEGF) and the P64K recombinant protein. In another embodiment, the present invention relates to the conjugation procedure to obtain, a chemical conjugated under controlled and reproducible parameters.In a preferred embodiment, the present invention relates to the procedure for purifying the chemical conjugated with a higher purity of the therapeutical vaccine composition, and a surprisingly increased immunogenic activity, inducing a significant increase of the anti-EGF antibody titers in humans.Additionally the present invention provides the methodology to obtain a vaccine composition in several dose presentations (total milligrams of conjugated EGF-P64K/vial). The versatility of the dose presentation allows increasing the immunization dose per patient, without increasing the frequency of injections and / or immunization sites. Besides, the present invention relates to a sanitary procedure for obtaining a vaccine composition for parenteral route in the cancer therap.
No. of claims: 23


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.